Patterns of response and acquired resistance to the programmed death‐1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma

Zalaudek, Iris; Corneli, Paola; Vernoni, S; Fedele, D.; Papa, Giovanni; Conforti, Claudio; Retrosi, Chiara; Vezzoni, Roberta; Fagotti, Serena; Longone, Michela; Farinazzo, Eleonora; Meo, Nicola di; Pizzichetta, Maria Antonietta

doi:10.1111/dth.13107

Cited by 3 publications

(2 citation statements)

References 7 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy has become a cornerstone for the treatment of many cancers, including cutaneous malignancies, and is currently indicated for melanoma, cSCC, BCC, and MCC treatment [ 12 , 13 , 14 , 15 , 16 ]. Immunotherapy drugs act by inhibiting immune checkpoints, eventually improving the activity of the immune system against the tumoral cells and reducing regulatory-T-cell-mediated immunosuppression [ 13 ].…”

Section: The Role Of Immunotherapy In Non-melanoma Skin Cancermentioning

confidence: 99%

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Zelin

Maronese

Dri

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together with rarer cutaneous cancers, such as Merkel cell carcinoma (MCC) and other forms of adnexal cancers. The majority of NMSCs can be successfully treated with surgery or radiotherapy, but advanced and metastatic stages may require systemic approaches such as immunotherapy with immune checkpoint inhibitors (ICIs). Summary: Since immunotherapy is not effective in all patients and can potentially lead to severe adverse effects, an important clinical question is how to properly identify those who could be suitable candidates for this therapeutic choice. In this paper, we review the potential features and biomarkers used to predict the outcome of ICIs therapy for NMSCs. Moreover, we analyze the role of immunotherapy in special populations, such as the elderly, immunocompromised patients, organ transplant recipients, and subjects suffering from autoimmune conditions. Key messages: Many clinical, serum, histopathological, and genetic features have been investigated as potential predictors of response in NMSCs treated with ICIs. Although this field of research is very promising, definitive, cost-effective, and reproducible biomarkers are still lacking and further efforts are needed to validate the suggested predictors in larger cohorts.

show abstract

Section: The Role Of Immunotherapy In Non-melanoma Skin Cancermentioning

confidence: 99%

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Zelin

Maronese

Dri

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recommended doses are 3 mg for kilograms of weight every 3 weeks as intravenous (iv) infusion for a period of 30 minutes. Among the different PD‐1 inhibitors, the number of patients treated is the widest, about 28 reported in the literature (Assam et al, ; Borradori et al, ; Chang et al, ; Degache et al, ; Deinlein et al, ; Ferrarotto, ; Lipson et al, ; Ravulapati et al, ; Stevenson et al, ; Tran et al, ; Winkler et al, ; Zalaudek et al, ), excluding the ongoing trials in Phase I and II (Licitra et al, ; Kudchadkar et al, ; Maubec et al, ). Although the larger number of reported cases, responses data are not enough and in addition with short period of follow‐up.…”

Section: Introductionmentioning

confidence: 99%

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

Corneli

Conforti

Retrosi

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent nonmelanoma skin cancer (NMSC). The majority of in situ cSCC [cSCC (Tis)] can be cured surgically, while local advanced and metastatic ones require other treatments, but there are no therapies approved by U.S. Food and Drug Administration (FDA). Available treatments for these stages included radiotherapy, chemotherapy as cisplatin, but responses to these treatments are usually of short duration. Programmed death‐1 (PD‐1) inhibitors (pembrolizumab, nivolumab, and cemiplimab) are an innovative immunologic treatment that now has been shown to be useful for the treatment of advanced cSCC. Nowadays, data about the response rate with the use of PD‐1 inhibitors in cSCC are still few and, especially, the duration of the response after the start of treatment is short. Moreover, the number of cases is too small to express the beneficial effects of these treatments, although most data reported in the literature show quite good response rates. This review focused on some of the studies and associated results through an interesting research on search engines of all the cases about these systemic drugs, analyzing effects and side effects, and the research has been conducted considering published cases since March 2016 to October 2019.

show abstract

Pembrolizumab

2020

Reactions Weekly

View full text Add to dashboard Cite

Patterns of response and acquired resistance to the programmed death‐1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma

Cited by 3 publications

References 7 publications

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

Pembrolizumab

Contact Info

Product

Resources

About